Sabizabulin

Summary

Sabizabulin (CHEMBL2163631) is a phase-3 clinical-stage small molecule; indicated across 5 conditions including severe acute respiratory syndrome and adult acute respiratory distress syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 5 conditions
• Clinical trials: 6
• Chemistry: 377.4 Da · C21H19N3O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2163631
Name	Sabizabulin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	53379371
Molecular formula	C21H19N3O4
Molecular weight	377.4
InChIKey	WQGVHOVEXMOLOK-UHFFFAOYSA-N

SMILES: COC1=CC(=CC(=C1OC)OC)C(=O)C2=CN=C(N2)C3=CNC4=CC=CC=C43

IUPAC name: [2-(1H-indol-3-yl)-1H-imidazol-5-yl]-(3,4,5-trimethoxyphenyl)methanone

Also known as: ABI-231, APP-111, Sabizabulin, Veru-111, VERU-111, SABIZABULIN

Parent form; salt/anhydrous children: CHEMBL5314569

Patent coverage: 155 distinct patent families (371 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 288 (78%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
severe acute respiratory syndrome	3	MONDO:0005091	EFO:0000694
adult acute respiratory distress syndrome	2	MONDO:0100130	MONDO:0100130
breast neoplasm	2	MONDO:0021100	MONDO:0007254
neoplasm	1	MONDO:0005070	EFO:0000616

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE2	3
PHASE3	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04842747	PHASE3	COMPLETED	VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study
NCT04844749	PHASE3	TERMINATED	Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent
NCT03752099	PHASE1/PHASE2	TERMINATED	To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer
NCT04388826	PHASE2	COMPLETED	COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111
NCT05008510	PHASE2	WITHDRAWN	P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .
NCT05079360	PHASE2	WITHDRAWN	Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).